Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy
Personalized neoantigen vaccines drive specific T-cell responses but are limited by complexity and variable efficacy. We highlight advances in antigen prioritization, mRNA engineering, and delivery, and the importance of combining these approaches with immune checkpoint blockade for clinical impact